Reviewer Disclosures
| Reviewer | Employment | Research Grant | Other Research Support | Speakers Bureau/Honoraria | Expert Witness | Ownership Interest | Consultant/Advisory Board | Other |
|---|---|---|---|---|---|---|---|---|
| Jeffrey L. Anderson | Intermountain Healthcare | None | None | None | None | None | None | None |
| Susan Bell | Vanderbilt University | NIH/NICHD (2K12HD043483–11)† | Eisenstein Women’s Heart Fund* | None | None | None | None | None |
| James Blankenship | Geisinger Medical Center | None | Tryton Medical*; Abiomed*; AstraZeneca*; Boston Scientific*; Regado Biosciences*; Volcano*; Abbott Vascular* (Principal Investigator at Geisinger Medical Center for multicenter industry-funded research trials sponsored by these companies) | None | None | None | None | None |
| Joseph P. Drozda | Mercy Health | None | None | None | None | None | None | My nondependent son is a sales representative for Boston Scientific Corporation† |
| Andrew E. Epstein | University of Pennsylvania | Biotronik†; Boston Scientific†; Medtronic; Sorin Medical†; St. Jude Medical† | None | None | Yes (1 current case)* | None | Boston Scientific†; Medtronic†; St. Jude Medical†; Population Health Research Institute* | None |
| Lee A. Fleisher | University of Pennsylvania | None | None | None | None | None | Member, Medical Advisory Board to Technical Expert Panel of Blue Cross/Blue Shield Association* | None |
| Rebecca Gary | Emory University | None | None | None | None | None | None | None |
| Sarah Goodlin | Portland VAMC | Medtronic* | None | None | None | None | None | None |
| Lawrence Izzo | State University of New York at Buffalo; Erie County Medical Center | None | None | None | None | None | None | None |
| Mariell Jessup | University of Pennsylvania Heart and Vascular Center | None | None | None | None | None | None | None |
| Glenn N. Levine | Baylor College of Medicine; Michael E. DeBakey Medical Center | None | None | None | None | None | None | None |
| Patrick O’Gara | Brigham and Women’s Hospital, Boston, MA | NHLBI, Cardiothoracic Surgery Network† | None | None | None | None | None | None |
| Catherine M. Otto | University of Washington School of Medicine | None | None | None | None | None | None | None |
| Lawrence Rudski | Jewish General Hospital, Montreal, Quebec | None | None | None | None | None | None | None |
| Nanette Wenger | Emory University School of Medicine | Gilead Sciences†; NHLBI†; Pfizer* | None | None | None | None | Amgen*; AstraZeneca*; Gilead Sciences† | None |
This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10,000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10, 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
†
Significant.